Deferred Tax Assets, Net of Valuation Allowance of Sunshine Biopharma Inc. from 31 Dec 2013 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary: Sunshine Biopharma Inc. quarterly Deferred Tax Assets, Net of Valuation Allowance in USD history and change rate from 31 Dec 2013 to 31 Dec 2024.
Sunshine Biopharma Inc. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending 31 Dec 2024 was $481,747, a 173% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Change (%)

Sunshine Biopharma Inc. Quarterly Deferred Tax Assets, Net of Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$481,747	+$304,983	+173%	31 Dec 2024	10-K	01 Apr 2025	2024	FY
Q4 2023	$176,764	-$124,529	-41%	31 Dec 2023	10-K	01 Apr 2025	2024	FY
Q4 2022	$301,293			31 Dec 2022	10-K	04 Apr 2023	2022	FY
Q4 2015	$0	$0		31 Dec 2015	10-K	25 Mar 2016	2015	FY
Q4 2014	$0	$0		31 Dec 2014	10-K	25 Mar 2016	2015	FY
Q4 2013	$0			31 Dec 2013	10-K	11 Mar 2015	2014	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.